BioAtla, Inc. (BCAB)
1.26
-0.06
(-4.55%)
USD |
OTCM |
Sep 08, 16:00
BioAtla Shareholders Equity (Quarterly) : -36.24M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -36.24M |
| March 31, 2026 | -37.31M |
| December 31, 2025 | -36.19M |
| September 30, 2025 | -31.24M |
| June 30, 2025 | -16.74M |
| March 31, 2025 | 0.547M |
| December 31, 2024 | 14.26M |
| September 30, 2024 | 22.97M |
| June 30, 2024 | 31.37M |
| March 31, 2024 | 49.72M |
| December 31, 2023 | 70.67M |
| September 30, 2023 | 94.70M |
| June 30, 2023 | 124.52M |
| March 31, 2023 | 156.43M |
| Date | Value |
|---|---|
| December 31, 2022 | 180.34M |
| September 30, 2022 | 142.63M |
| June 30, 2022 | 164.95M |
| March 31, 2022 | 190.05M |
| December 31, 2021 | 210.82M |
| September 30, 2021 | 230.65M |
| June 30, 2021 | 178.02M |
| March 31, 2021 | 195.92M |
| December 31, 2020 | 209.97M |
| September 30, 2020 | -74.52M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -55.96M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 9.506M |
| Total Liabilities (Quarterly) | 45.74M |
| Debt to Equity Ratio | -0.1618 |
| Current Ratio | 0.2026 |
| Net Debt Paydown Yield | -15.42% |